Health Care/Hospital

Baird Medical Granted New Class III Certificate by China's NMPA for Ceramic Thyroid Ablation Needle

FRISCO, Texas, March 29, 2024 /PRNewswire/ -- Baird Medical Devices, Inc. ("Baird Medical" or the "Company"), a leading microwave ablation ("MWA") medical device developer and provider inChina and the United States, today announced it has been granted a new Class III certificate by the National ...

2024-03-29 21:37

LISCure Biosciences receives U.S. FDA Fast Track designation for LB-P8 for the treatment of primary sclerosing cholangitis (PSC)

* Phase 2 study is underway and LB-P8 is the only live biotherapeutic product currently reported to be in clinical development for the treatment of PSC * FDA's Fast Track designation for LB-P8 underlines the urgent need for treatment options to fulfill the unmet medical needs of people affecte...

2024-03-29 21:00 203

73% CNS ORR! FDA Granted ODD to Utidelone Injectable (UTD1) from Biostar Pharma for the Treatment of Breast Cancer Brain Metastasis

SAN FRANCISCO, March 29, 2024 /PRNewswire/ -- Biostar Pharma, Inc., the U.S. subsidiary of Beijing Biostar Pharmaceuticals Co., Ltd. which is a synthetic biology driven biopharma company focusing on the development and commercialization of innovative oncology drugs, announced today that their cor...

2024-03-29 20:40 317

Alebund's Innovative Investigational Drug AP303 Receives FDA Orphan Drug Designation (ODD) for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

SHANGHAI, March 29, 2024 /PRNewswire/ -- Alebund Pharmaceuticals ("Alebund" or the "Company"), an integrated biopharmaceutical company focusing on developing innovative therapies for the treatment of renal diseases and related chronic conditions, announced today that th...

2024-03-29 20:00 437

IASO Bio Announces NMPA's IND Approval for Equecabtagene Autoleucel in Second- and Third-Line Treatment of Multiple Myeloma

SHANGHAI and NANJING, China and SAN JOSE, Calif., March 29, 2024 /PRNewswire/ -- IASO Bio, a biopharmaceutical company engaged in discovering, developing, manufacturing and marketing innovative cell therapies and antibody products, today announced thatChina National Medical Products Administratio...

2024-03-29 17:20 595

Jacobio Pharma Announces 2023 Annual Results

BEIJING, SHANGHAI and BOSTON, March 28, 2024 Jacobio/PRNewswire/ --  Pharma (1167.HK), a clinical-stage oncology company drugging the undruggable targets, today announced its 2023 annual results. The revenue wasRMB63.5 million, the R&D investment wasRMB372 million, the cash and cash equivalent at...

2024-03-29 08:50 1156

Bridge Biotherapeutics Launches a Research Collaboration with Emory University School of Medicine to Explore Combination Therapy of BBT-877 for KRAS/P53 Mutant NSCLC Patients Resistant to Anti-PD-1 Blockade

SEONGNAM, South Korea and ATLANTA, March 28, 2024 /PRNewswire/ --  Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Jessica M...

2024-03-29 06:00 1394

Harbour BioMed Reports Full Year 2023 Financial Results

CAMBRIDGE, Mass., ROTTERDAM, Netherlands and SUZHOU, China, March 28, 2024 /PRNewswire/ -- Harbour BioMed ("HBM" or the "Company"; HKEX: 02142), a global biopharmaceutical company committed to the discovery, development and commercialization of novel antibody therapeutics focusing on immune-oncol...

2024-03-28 22:10 1106

Keosaa Launches Debut Electric Toothbrush on Amazon for Enhanced Oral Care

NEW YORK, March 28, 2024 /PRNewswire/ -- In an exciting announcement for dental hygiene enthusiasts and tech-savvy consumers alike, Keosaa has just launched its latest line of electric toothbrushes for a brighter, healthier smile. As we celebrate Oral Health Month, there is a better time to upgra...

2024-03-28 21:00 758

Primech Holdings Limited Provides Financial Updates and Corporate Highlights For the Six Months Ended September 30, 2023

SINGAPORE, March 28, 2024 /PRNewswire/ -- Primech Holdings Limited (Nasdaq: PMEC) ("Primech" or the "Company"), an established technology-driven facilities services provider in the public and private sectors operating mainly inSingapore , provides a financial and corporate update coincident with t...

2024-03-28 20:30 1304

GenFleet and BeiGene Enter into Trial Collaboration for a Potentially First-in-class Combination Therapy to Initiate Phase Ib/II Study of GFH009 (CDK9 inhibitor) and BRUKINSA® (zanubrutinib) Treating Diffuse Large B Cell Lymphoma

SHANGHAI, March 28, 2024 /PRNewswire/ -- GenFleet Therapeutics, a clinical-stage biotechnology company focusing on cutting-edge therapies in oncology and immunology, today announced it has entered into a clinical trial collaboration and supply agreement with BeiGene Switzerland GmbH to start a c...

2024-03-28 19:00 1129

Tigermed Reports Full Year 2023 Results

HANGZHOU, China, March 28, 2024 /PRNewswire/ -- Hangzhou Tigermed Consulting Co., Ltd. ("Tigermed" or the "company") (Stock code: 300347.SZ / 3347.HK), a leading global provider of integrated research and development solutions for biopharmaceutical and medical device industry, announced its annua...

2024-03-28 18:31 1167

Ascentage Pharma Announces 2023 Annual Results

SUZHOU, China and ROCKVILLE, Md., March 27, 2024 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced its annual results for the full year 2023. During...

2024-03-27 22:30 1615

CARsgen Announced 2023 Annual Results

SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights * Z...

2024-03-27 20:50 1479

Sanyou Bio: Sanyou's Intelligence-Enabled Innovative Biologics R&D Platform Leads in the New Era of Biological Drug Development

SHANGHAI, March 27, 2024 /PRNewswire/ -- Dr. Guojun Lang, founder and CEO of Sanyou Biopharmaceuticals provides industry insights: The new era sees the transition towards digitalization and intelligence. Following this trend, we have been thinking and planning the transformative path of digitali...

2024-03-27 20:00 970

YolTech Therapeutics to Participate in 2024 Cell & Gene Meeting on the Mediterranean

SHANGHAI, March 27, 2024 /PRNewswire/ -- YolTech Therapeutics, a trailblazing biopharmaceutical company specializing in gene editing, is delighted to announce its participation in 2024 Cell & Gene Meeting on the Mediterranean. The event will take place fromApril 9th to 11th, 2024, at the esteemed...

2024-03-27 20:00 775

Waterdrop declared a special cash dividend, the aggregate payment of which amounted to approximately US$15 million

BEIJING, March 27, 2024 /PRNewswire/ -- Waterdrop Inc. (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, today announced its unaudited financial results for the three months and full year endedDecember 31, 2023 and a special ca...

2024-03-27 14:35 1260

Bridge Biotherapeutics Announces a Research Collaboration with the University of Colorado School of Medicine to Explore Potential of BBT-877 for Immuno-Oncology

SEONGNAM, South Korea and AURORA, Colo., March 26, 2024 /PRNewswire/ -- Bridge Biotherapeutics (KQ288330) , a South Korean clinical-stage biotech company developing novel drugs for cancer, fibrosis, and inflammation, announced a research collaboration with Dr.Raul...

2024-03-27 06:00 266

Keymed Biosciences Announces 2023 Annual Results and Business Updates

* Submitted a New Drug Application (NDA) of Stapokibart (CM310) for the treatment of moderate-to-severe AD in adults. The NDA was accepted by theChina's NMPA and granted priority review. * Advanced a Phase III clinical study of Stapokibart for the treatment of CRSwNP in 2023. The results of t...

2024-03-27 01:16 588

Datasea Enters into 5G AI Multimodal Communication Cooperation Agreement Expected to Expand its China 5G Services Revenue

The Agreement with an Estimated Value of $30 Million Supports its Revenue Guidance of$86 Million, a 1,128% Year-Over-Year Increase for its Full Fiscal Year BEIJING, March 26, 2024 /PRNewswire/ -- Datasea Inc. (NASDAQ: DTSS) ("Datasea" or the "Company"), aNevada corporation engaged in innovative ...

2024-03-26 22:00 805
12345 ... 252